New search Hide text from Guidelines
N NERVOUS SYSTEMN04 ANTI-PARKINSON DRUGS
This group comprises preparations used in the treatment of Parkinsons disease and related conditions, including drug-induced parkinsonism.
| The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease. No separate DDDs are established for oral depot formulations. |
N04B DOPAMINERGIC AGENTS
N04BC Dopamine agonists
Bromocriptine used in parkinsonism is classified in this group (e.g. tablets of 5 mg and 10 mg). Low strength bromocriptine tablets (e.g. 2.5 mg) used as a prolactine inhibitor are classified in G02CB - Prolactine inhibitors.
Cabergoline used in parkinsonism is classified in this group (e.g. tablets of 1 mg). Low strength cabergoline tablets (0.5 mg) used as a prolactine inhibitor are classified in G02CB.
Lisuride in high strength formulations (e.g. 0.2 mg tablets), which is also used in the treatment of Parkinsonism, are classified in G02CB while lisuride in low strength formulations (e.g. 25 mcg tablets) are classified in N02CA.
| ATC code | Name | DDD | U | Adm.R | Note |
| N04BC04 | ropinirole | 6 | mg | O |
Last updated: 2024-01-26